Extracorporeal Photopheresis - An Overview

被引:79
作者
Cho, Ara [1 ]
Jantschitsch, Christian [1 ]
Knobler, Robert [1 ]
机构
[1] Med Univ Wien, Dept Dermatol, Vienna, Austria
关键词
ECP; ultraviolet A; CTCL; GVHD; scleroderma; solid organ transplantation; VERSUS-HOST-DISEASE; T-CELL LYMPHOMA; HEART-TRANSPLANT REJECTION; SEVERE ATOPIC-DERMATITIS; BRONCHIOLITIS OBLITERANS SYNDROME; CONSENSUS DEVELOPMENT PROJECT; SYSTEMIC-SCLEROSIS; CLINICAL-TRIALS; DENDRITIC CELLS; CROHNS-DISEASE;
D O I
10.3389/fmed.2018.00236
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after receiving FDA approval for the palliative treatment of the Sezary Syndrome variant of cutaneous T-cell lymphoma (CTCL) in 1988. After the first positive experiences with CTCL, additional indications have been successfully explored including areas such as graft-vs.-host disease (GVHD), scleroderma, and solid organ transplantation. The mechanism of action is still not fully resolved, but important steps in understanding ECP in recent years have been very informative. Originally, the primary hypothesis stated that psoralen and ultraviolet A (UVA) in combination induce apoptosis in the treated immune cells. This view shifted in favor of dendritic cell initiation, modification of the cytokine profile and stimulation of several T-cell lineages, in particular regulatory T-cells. A number of ECP guidelines have been produced to optimize treatment regimens in the clinical context. In CTCL, enough evidence is available for the use of ECP as a first line treatment for Sezary Syndrome (SS), but also as a second line or rescue treatment in therapy-refractory forms of mycosis fungoides (MF). ECP in the treatment of acute and chronic GVHD has shown promising results as second line therapy in steroid-refractory presentations. In solid organ transplantation, ECP has been used to increase tissue tolerance and decrease infections with opportunistic pathogens, attributed to the use of high doses of immunosuppressive medication. Infection with cytomegalovirus (CMV) remains a limiting factor affecting survival in solid organ transplantation and the role of ECP will be discussed in this review. A trend toward prophylactic use of ECP can be observed and may further contribute to improve the outcome in many patients. To further deepen our knowledge of ECP and thus facilitate its use in patients that potentially benefit most from it, future prospective randomized trials are urgently needed in this rapidly growing field. The aim of this review is to (1) introduce the method, (2) give an overview where ECP has shown promising effects and has become an essential part of treatment protocols, and (3) to give recommendations on how to proceed in numerous indications.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Extracorporeal photopheresis and liver transplantation: Our experience and preliminary data
    Mazzoni, A.
    Giampietro, C.
    Bianco, I.
    Grazzini, T.
    Nencini, C.
    Pileggi, C.
    Scatena, F.
    Filipponi, F.
    Ghinolfi, D.
    Catalano, G.
    Biancofiore, G.
    Bindi, M. L.
    Urbani, L.
    TRANSFUSION AND APHERESIS SCIENCE, 2017, 56 (04) : 515 - 519
  • [32] Extracorporeal photopheresis induces the release of anti-inflammatory fatty acids and oxylipins and suppresses pro-inflammatory sphingosine-1-phosphate
    Hagn, Gerhard
    Cho, Ara
    Zila, Nina
    Sterniczky, Barbara
    Jantschitsch, Christian
    Dong, Dexin
    Bileck, Andrea
    Koren, Mariia
    Paulitschke, Philipp
    Mohr, Thomas
    Knobler, Robert
    Weninger, Wolfgang Peter
    Gerner, Christopher
    Paulitschke, Verena
    INFLAMMATION RESEARCH, 2025, 74 (01)
  • [33] The role of the extracorporeal photopheresis in the management of the graft-versus-host disease
    Kaloyannidis, Panayotis
    Mallouri, Despina
    TRANSFUSION AND APHERESIS SCIENCE, 2012, 46 (02) : 211 - 219
  • [34] Extracorporeal photopheresis: tolerogenic or immunogenic cell death? Beyond current dogma
    Hannani, Dalil
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [35] Extracorporeal photopheresis: what is it and when should it be used?
    Scarisbrick, J.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2009, 34 (07) : 757 - 760
  • [36] Extracorporeal Photopheresis for Non-skin GvHD
    Bittenbring, Joerg
    Reichrath, Joerg
    ANTICANCER RESEARCH, 2016, 36 (03) : 1395 - 1396
  • [37] Extracorporeal photopheresis in prevention and treatment of acute GVHD
    Kitko, Carrie L.
    Levine, John E.
    TRANSFUSION AND APHERESIS SCIENCE, 2015, 52 (02) : 151 - +
  • [38] EXTRACORPOREAL PHOTOPHERESIS IN THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST- DISEASE
    Vasilyeva, V. A.
    Kuzmina, L. A.
    Drokov, M. Yu
    Dovydenko, M., V
    Koroleva, O. M.
    Dubnyak, D. S.
    Dmitrova, A. A.
    Nikiforova, N. M.
    Starikova, O. S.
    Komelskikh, D., V
    Sherbakova, A. A.
    Gaponova, T., V
    Parovichnikova, E. N.
    Savchenko, V. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2022, 67 (02): : 202 - 215
  • [39] EXTRACORPOREAL PHOTOPHERESIS IN A RAT MODEL OF PULMONARY FIBROSIS
    Remund, Kaspar
    Rechsteiner, Thomas
    Guo, Zhongning
    Hofer, Markus
    Boehler, Annette
    EXPERIMENTAL LUNG RESEARCH, 2009, 35 (05) : 359 - 370
  • [40] Recent insights into extracorporeal photopheresis for graft-versus-host disease
    Del Fante, Claudia
    Perotti, Cesare
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (04) : 339 - 348